北大医药2026年第一次临时股东会通过多项议案，涉及利润分配、关联交易及薪酬制度

Core Viewpoint - The company held its first extraordinary general meeting of shareholders for 2026 on January 28, 2026, where all six proposals were approved, indicating a strong consensus among shareholders on key decisions [1] Group 1: Meeting Outcomes - The profit distribution plan for the first three quarters of 2025 was approved with a high approval rate of 99.8368% [1] - The company approved the expected daily related transactions for 2026 with Chongqing Southwest Synthetic Pharmaceutical Co., Ltd., China Ping An Insurance (Group) Co., Ltd., and other related parties [1] - The bank credit financing plan for 2026 and the provision of guarantees were also approved [1] Group 2: Governance and Management - The management system for the remuneration (allowances) of directors and senior management was reviewed and approved [1] - The remuneration (allowances) plan for directors for 2026 was also approved, indicating a structured approach to governance [1] Group 3: Participation and Voting - A total of 451 shareholders and proxies attended the meeting, representing 207 million shares, which is 34.7542% of the total voting shares [1] - Related party proposals were voted on with the required avoidance of related shareholders, ensuring compliance with regulations [1]